Lansdale, PA, United States of America

John P Imredy


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by John P. Imredy in Electrical Field Stimulation

Introduction

John P. Imredy is an innovative inventor based in Lansdale, PA, whose work has significantly contributed to the understanding of voltage-gated ion channels. With a background in biotechnology and a focus on cellular manipulation, he has developed methods that enhance experimental precision in this critical area of research.

Latest Patents

John P. Imredy's noteworthy patent, titled "Electrical Field Stimulation of Eukaryotic Cells," presents methods of identifying activators and inhibitors of voltage-gated ion channels. This innovative technique utilizes electrical field stimulation to influence the open/close state transitions of these channels, thereby allowing for more convenient and precise manipulation in experiments. The patent showcases how these methods can be effectively employed in high throughput screening, ultimately advancing the field of cellular biology.

Career Highlights

John is currently associated with Merck & Company, Inc., where he continues to explore the frontiers of biotechnology. His work has positioned him as a prominent figure in research circles, particularly for his contributions towards understanding and manipulating eukaryotic cell behavior.

Collaborations

Throughout his career, John has collaborated with esteemed colleagues such as Paul R. Augustine and Randal M. Bugianesi. Together, they have worked on various projects that combine their expertise, driving forward their understanding and application of ion channel manipulation within biological systems.

Conclusion

John P. Imredy stands out as a pivotal innovator in the study of voltage-gated ion channels. His groundbreaking patent not only enhances the methods of conducting experiments but also provides tools for high throughput screening, which could lead to significant advancements in medical and biological research. As he continues his work at Merck & Company, Inc., the future looks promising for advancements in this critical area of study.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…